#151060

Anti-DAF [67]

Cat. #151060

Anti-DAF [67]

Cat. #: 151060

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: Decay accelerating factor (DAF, CD55)

Class: Monoclonal

Application: FACS ; IHC ; IF ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Nancy Hogg

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-DAF [67]
  • Alternate name: CD55
  • Clone: 67
  • Tool type ecom: Antibodies
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 79 kDa
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: FACS ; IHC ; IF ; WB
  • Description: Decay Accelerating Factor is a distinctive marker of synovium. Decay Accelerating Factor protects tissues from attack by autologous complement by interfering with the assembly of C3 convertase.
  • Immunogen: Fibronectin purified human monocytes .
  • Isotype: IgG1
  • Myeloma used: Sp2/0-Ag14

Target Details

  • Target: Decay accelerating factor (DAF, CD55)
  • Molecular weight: 79 kDa
  • Target background: Decay Accelerating Factor is a distinctive marker of synovium. Decay Accelerating Factor protects tissues from attack by autologous complement by interfering with the assembly of C3 convertase.

Applications

  • Application: FACS ; IHC ; IF ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -80° C
  • Shipping conditions: Shipping at 4° C

References

  • Gheorghe et al. 2011. PLoS One. 6(1):e16378. PMID: 21298002.
  • Prostaglandin E2 synthesizing enzymes in rheumatoid arthritis B cells and the effects of B cell depleting therapy on enzyme expression.
  • Kamada et al. 2009. Pathol Int. 59(6):382-9. PMID: 19490468.
  • Leitinger et al. 2002. J Cell Sci. 115(Pt 5):963-72. PMID: 11870215.
  • The involvement of lipid rafts in the regulation of integrin function.
  • Palmer et al. 1985. Clin Exp Immunol. 59(3):529-38. PMID: 3886218.
  • Features of synovial membrane identified with monoclonal antibodies.